Nanoparticulate carriers for the treatment of coronary restenosis by Brito, Luis & Amiji, Mansoor
International Journal of Nanomedicine 2007:2(2) 143–161
© 2007 Dove Medical Press Limited. All rights reserved
143
REVIEW
Nanoparticulate carriers for the treatment 
of coronary restenosis
Luis Brito
Mansoor Amiji
Department of Pharmaceutical 
Sciences, School of Pharmacy, 
Northeastern University, Boston, MA, 
USA
Correspondence: Mansoor Amiji
Department of Pharmaceutical Sciences, 
School of Pharmacy, Northeastern 
University, 110 Mugar Life Sciences 
Building, Boston, MA 02115, USA
Tel +1 617 373 3137
Fax +1 617 373 8886
Email m.amiji@neu.edu
Abstract: The current treatment for coronary restenosis following balloon angioplasty 
involves the use of a mechanical or a drug-eluting stent. Despite the high usage of 
commercially-available drug-eluting stents in the cardiac ﬁ  eld, there are a number of 
limitations. This review will present the background of restenosis, go brieﬂ  y into the molecular 
and cellular mechanisms of restenosis, the use of mechanical stents in coronary restenosis, 
and will provide an overview of the drugs and genes tested to treat restenosis. The primary 
focus of this article is to present a comprehensive overview on the use of nanoparticulate 
delivery systems in the treatment of restenosis both in-vitro and in-vivo. Nanocarriers have 
been tested in a variety of animal models and in human clinical trials with favorable results. 
Polymer-based nanoparticles, liposomes, and micelles will be discussed, in addition to the 
ﬁ  ndings presented in the ﬁ  eld of cardiovascular drug targeting. Nanocarrier-based delivery 
presents a viable alternative to the current stent based therapies. 
Keywords: coronary restenosis, stents, nanoparticulate carriers, liposomes, polymeric nanopar-
ticles, micelles, drug delivery, gene therapy
Introduction
In 2004, cardiovascular diseases were the number one cause of death in the United 
States according to the National Center for Health Statistics (Lethbridge-Çejku et al 
2006). Over 24 million people in the United States have been diagnosed with some 
type of heart disease. (Lethbridge-Çejku et al 2006). Atherosclerosis is a condition 
where plaque forms on the arterial vessel wall. The plaque occludes the vessel, 
increasing the chance of a clot causing an obstruction to blood ﬂ  ow. When located in 
the heart, the obstruction leads to ischemia, myocardioal infarction, and can lead to 
death. Removal of the plaque is currently performed by invasive techniques, such as 
percutaneous transluminal coronary angioplasty (PTCA), atherectomy, and stenting. 
These techniques all can lead to a complication called restenosis, where the vessel 
closes upon itself again, in a different mechanism to atherosclerosis. The placement of 
stents has become the treatment of choice compared to PTCA due to its lower percent-
age of restenosis (Kastrati et al 2001). Alternatively, bypass surgery can be used to 
remove the occluded artery and replace it with a blood vessel from another part of the 
body, usually the saphenous vein from the leg. Stenting has been compared to bypass 
surgery and has shown similar results after a one-year follow up with signiﬁ  cantly 
lower cost (Serruys et al 2001).
Coronary restenosis is caused by an injury to the arterial vessel wall that induces 
a series of events leading to restenosis based on the three main procedures used to 
remove plaque. PTCA is where a small balloon is inserted into the effected blood 
vessel. The balloon is then inﬂ  ated and compresses the atherosclerotic plaque, this International Journal of Nanomedicine 2007:2(2) 144
Brito and Amiji
procedure is also called balloon angioplasty. Another 
procedure is called atherectomy; this is where the plaque is 
scraped, brushed, and vacuumed out. Arterial wall damage 
occurs during the mechanical scraping and brushing stage 
resulting in denudation. The ﬁ  nal cause of restenosis is due 
to the insertion of a stent at the site of the atherosclerotic 
plaque. This ﬁ  ne metal wire tube was designed to reduce 
restenosis caused by balloon angioplasty. Restenotic lesions 
caused by stents and angioplasty are very different at the 
molecular level, though clinically the pathological outcome 
is the same (Scott 2006). 
Deﬁ  nition of restenosis
Goldberg and colleagues (2001) have deﬁ  ned restenosis as 
a greater than 50% narrowing of the vessel as determined by 
a follow-up angiogram. Clinically, restenosis is an injury-
induced effect on the arterial wall. This effect is typically 
classiﬁ  ed into two distinct steps, smooth muscle cell (SMC) 
proliferation, typically called neointimal hyperplasia or 
intimal hyperplasia, and vessel remodeling (Costa and 
Simon 2005). As previously mentioned, restenosis 
caused by balloon angioplasty is distinctly different 
from angioplasty caused by placement of metallic stents. 
Restenosis caused by balloon angioplasty is attributed to 
three different factors: the elastic response that occurs after 
the overstretching of the vessel, neointimal formation, and 
chronic remodeling (Scott 2006). Neointimal formation 
associated with balloon angioplasty is primarily formed by 
the adventitia, with some proliferation of the media layer. 
Stent-induced restenosis is primarily caused by prolifera-
tion and accumulation in the intimal layer, leading to a 
growth of the neointima (Hoffmann et al 1996). Vascular 
remodeling in this case is not as deﬁ  ned as in balloon 
induced injury (Nakatani et al 2003). 
Involvement of different cell types
The types of cells involved in the restenotic process are well 
documented. There are three primary layers in a healthy blood 
vessel. The tunica intima or intimal layer is the innermost 
layer and is in contact with the blood ﬂ  owing through the 
artery. This layer consists primarily of endothelial cells. 
Adjacent to the intimal layer is the tunica media or medial 
layer, consisting of primarily smooth muscle cells. This 
layer is responsible for the vascular tone. The outermost 
layer is the tunica adventitia or adventitial layer, consisting 
of primarily collagen, to provide structure and elasticity. 
Following vascular injury, other cells are recruited including 
various inﬂ  ammatory cells, such as macrophages, T-cells 
and a small number of B-cells (Farb et al 2002). There is 
a degree of similarity between restenosis and wound heal-
ing. Analysis of the extracellular matrix of a restenotic lesion 
showed hyaluronan and collagen, which are also both involved 
in would healing process (Farb et al 2004; Scott 2006). Figure 1 
shows an illustration of the different steps in the formation 
of a restenotic lesion. 
Molecular signals in restenosis
After stent placement, various molecular markers signals 
are activated in the coronary artery (Welt and Rogers 
2002). Inﬂ  ammatory signals play a major role in restenosis 
and correlates with the amount of injury at the site of stent 
deployment (Kornowski et al 1998). With increase in the 
inﬂ  ammatory process in the injured arterial wall, there is 
greater proliferation of SMC and narrowing of the artery. 
As soon as 15 minutes after injury to the vessel, activated 
leukocytes invade the site of injury which further leads 
to the deposition of neutrophils, monocytes, platelets and 
ﬁ  brinogen (Farb et al 2002). Macrophages are recruited 
within the neointima as well. The recruitment of ﬁ  brinogen 
receptors and neutrophils up-regulate adhesion receptors on 
the cell surface (Kornowski et al 1998). A week after stent 
placement, cytokines including monocyte chemoattractant 
protein-1 (MCP-1), interleukin-6 (IL-6) and interleukin-8 
(IL-8) are recruited depending on the type of injury causing 
an potent pro-inﬂ  ammatory response. A leukocyte integrin 
class of adhesion molecules Mac-1 interacts with activated 
platelet receptors (P-selectin glycoprotein) leading to an ac-
cumulation of platelets on the intimal wall (Costa and Simon 
2005). It was found that the blockade of CCR2 was able to 
reduce neointimal hyperplasia in stented vessels, while hav-
ing no effect on balloon injured vessels (Horvath et al 2002). 
Targeting leukocyte β2-integrin MAC-1 (CD11b/CD18) was 
shown to reduce neointimal hyperplasia in balloon-injured 
models (Horvath et al 2002). In balloon-injured models, it 
was shown that although there was no macrophage inﬁ  ltration 
in the neointima, there was signiﬁ  cant neutrophil inﬁ  ltration 
(Welt et al 2000). 
There are a number of growth factors and cytokines that 
play a role in restenosis. Fibroblast growth factor (FGF), 
platelet-derived growth factor (PDGF) A and B, insulin 
like growth factors (IGF), and transforming growth factor 
β (TGF-β) are produced by SMC’s and are responsible for 
the SMC proliferation (Welt and Rogers 2002). Additionally 
PDGF A and B, released from SMC’s, platelets, and 
endothelial cells, are responsible for SMC migration. Vascular 
endothelial growth factor (VEGF) derived from endothelial International Journal of Nanomedicine 2007:2(2) 145
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cells is responsible for endothelialization and angiogenesis. 
The cytokines involved in restenosis are MCP-1, IL-8, and IL-6 
(Welt and Rogers 2002). These cytokines, which are present 
early in the process, are responsible for monocyte and neutro-
phil recruitment and are derived from a number of cells such as 
macrophages, SMCs, endothelial cells, ﬁ  broblasts, T-cells and 
polymorphonuclear leukocytes. The cytokine signals are key 
indicators of an inﬂ  ammatory response at the site of damage. 
Another molecular signal associated with inﬂ  ammation and 
restenosis is the β-2 integrin molecule Mac-1 (CD11b/CD18), 
which is responsible for monocyte recruitment (Scott 2006). 
In addition to the inﬂ  ammatory factors mentioned, other pro-
teins or enzymes are effected by restenosis, including p27, 
p70, p16, TGF-β, and collagen (Costa and Simon 2005). 
For additional understanding on the molecular signaling and 
inﬂ  amation involved in restenosis, the reader is referred to 
excellent reviews of the subject (Libby and Tanaka 1997; 
Welt and Rogers 2002; Costa and Simon 2005; Gaspardone 
and Versaci 2005; Scott 2006). 
Therapeutic strategies 
for restenosis
There are a variety of different ways to treat restenosis. 
Mechanical stents that keep the vessel open have been coated 
with drugs to prevent the cells from growing into the vessel 
lumina. A variety of different drug classes have been used to 
treat restenosis, including anti-cancer and anti-inﬂ  ammatory 
agents. Modulation of genes with plasmid DNA and RNA 
interference have been used to create an increase or decrease 
in the local concentrations of speciﬁ  c signaling molecules 
used to inhibit the growth of certain cells, while promot-
ing the growth of others. The key point for each of these 
therapies is to inhibit the growth of SMCs, while promoting 
re-endothelialization of the vessel, such as to reverse the 
injured vessel back into a healthy vessel. 
Mechanical stents
Originally used by Dr. Charles Stent, a dentist, in the year 
1856 for facial reconstruction, this device has radically 
changed noninvasive cardiac intervention in the early 1990’s 
(Schatz et al 1991; Ring 2001). Stent usage has continuously 
grown and is now a widely accepted treatment for occluded 
arteries (Topol 1998; Tung et al 2006b). The use of balloon 
angioplasty to remove a clot is associated with a greater 
than 40% restenosis rate, with greater percent restenosis 
in larger vessels (Elezi et al 1999). The advent of the bare 
metal stent reduced the incidence of restenosis to 20–53% 
depending on the type of stent used (Kastrati et al 2001). 
An important design feature of stents is the thickness of the 
stent strut, with the thicker struts causing greater incidence of 
restenosis (Pache et al 2003). The drug-eluting stent (DES) 
further reduced the percentage of restenosis to less than 10% 
Figure 1 Schematic illustration of the processes leading to restenotic lesion development. The ﬁ  gures show a healthy blood vessel (A), formation of atherosclerotic plaque 
within the blood vessel showing a fatty streak and macrophages encapsulated within a ﬁ  brotic tissue (B), insertion of a balloon angioplasty catheter to remove the plaque 
(C), damage due to stripping of the endothelial cells of the vessel wall after removal of the balloon (D), platelet accumulation and activation as well as rapid growth of 
smooth muscle cells and ﬁ  brous extracellular matrix forming the scaffolding (E), and the late stage restenosis showing neointima protruding into the lumen causing occlu-
sion within the vessel (F).
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in initial clinical trials (Degertekin et al 2003; Stone et al 
2004). These results have lead to the current use of DES in 
greater than 85% of all coronary interventions (Kandzari 
et al 2005). The use of bare metal stents has fallen sharply 
since the introduction of DES, though that seems to be chang-
ing with the current studies showing that DES can lead to 
possible life threatening in-stent thrombosis conditions (Tung 
et al 2006b). In-stent thrombosis, or the formation of blood 
clots, occurs more frequently in DES as compared to bare 
metal stents since it is shown to occur prior to cell healing. 
In general, DES prolong the healing process and, as such, are 
more prone to thrombotic events (Tung et al 2006b). Despite 
the high usage of DES in the interventional cardiology ﬁ  eld, 
there is still substantial opportunity for improvement. The 
polymer coating on stent surface is thought to invoke an 
inﬂ  ammatory response at the site of injury creating a potential 
for restenosis (Virmani et al 2004).
Currently there are two DES on the market, the Cypher® 
stent and the Taxus® stent. Each stent has a different drug 
and coating on it. The Cypher® stent is loaded with sirolimus, 
which is also known as rapamycin, coated on the surface with 
a poly(ethylene-co-vinyl acetate) (PEVA) and poly(n-butyl 
methacrylate) (PBMA) nonerodable and nonthrombogenic 
polymers (Vishnevetsky et al 2004). Sirolimus is a cytostatic 
agent causing cell cycle arrest arrest in the G1 phase of cell 
division (Braun-Dullaeus et al 1998). The Taxus® stent has 
the drug paclitaxel embedded in a poly(styrene-b-isobutylene-
b-styrene) (SIBS) triblock elastomeric polymer (Ranade et al 
2004). Similarly to sirolimus, paclitaxel is a cytostatic agent, 
arresting cell division in the G1 phase (Ranade et al 2004). For 
reviews on the clinical performance of the Cypher® and Taxus® 
stents, please refer to the following reviews (Vishnevetsky et al 
2004; Nawarskas and Osborn 2005). 
Alternative stent designs have been tested including 
the use of biodegradable polymer-based stents to inhibit 
restenosis after initial implantation and then having them 
degrade in situ after the vessel has stabilized. Poly(L-lactic 
acid)-based biodegradable stent has been used in humans 
with favorable results, showing complete degradation after 
6 months (Tamai et al 2000). The researchers did not evaluate 
the length of time the required for the stent to degrade or if 
the acidic bi-products of the degraded stent had unfavorable 
interactions with the vessel wall. A limitation of polymer 
based stents is that they may not be mechanically as strong 
as the metal-based stent. An alternative approach to using 
polymeric materials, is the use of a magnesium-based stent 
that will corrode in the body leaving no metal behind after a 
period of set time (Di Mario et al 2004). A follow up clini-
cal study showed that the magnesium stent was absorbed 
within 3 weeks of implantation (Bose et al). More studies are 
necessary to show whether the residence time of the device 
is appropriate as vessel remodeling is likely to occur for at 
least a month after clearing of the vessel. A recent review by 
Waksman provides an excellent overview of the bioabsorable 
stents (Waksman 2006). 
Other approaches to stent design include removal of the 
polymer-drug reservoirs, and replacing them with nonpolymeric 
nanoporous reservoirs. The use of carbon-coated stents has 
been shown to have comparable results to current metal-based 
DES (Bhargava et al 2006). However, additional studies will 
have to be performed under the United States Food and Drug 
Administration guidelines to conﬁ  rm these preliminary ﬁ  nd-
ings. Nanoporous aluminum oxide-coated stents have also been 
loaded with potent immunosuppressant tacromilus and shown 
to inhibit neointimal growth (Wieneke et al 2003). Subsequent 
studies seem to contradict these ﬁ  ndings, concluding that particle 
debris from these stents could negate any positive inhibition of 
restenosis (Wieneke et al 2003; Kollum et al 2005). Additional 
issues such as thrombosis and inﬂ  ammatory response to these 
implantable devices need to be well understood before they are 
considered clinically viable alternatives. 
Drug therapy strategies
The advent of DES has brought the use of therapeutic agents 
and genes to treat restenosis to the forefront of cardiovascular 
research. A variety of different drug classes have been experi-
mented for the prevention of SMC growth and proliferation. 
Antineoplastic agents, such as cytarabine, doxorubicin, and 
vincristine have been tested to determine their effects on 
SMC growth with some success (Voisard et al 1993). Voisard 
et al have also tested doxorubicin in addition to four other 
drugs – dalteparin sodium, cyclosporine A, colchicines, and 
etoposide – on whether the SMC proliferation was inhibited 
(Voisard et al 1995). Each of these agents showed some 
degree of SMC growth inhibition. 
Sirolimus, also known as rapamycin, has been shown to 
inhibit SMC growth in rat cells and in human cell in cultures 
(Marx et al 1995). Sirolimus was later approved for use in 
the Cypher® brand DES developed by Cordis in conjunction 
with Johnson and Johnson and is now a common treatment 
for restenosis. 
Initial studies using paclitaxel, a microtubule stabiliz-
ing chemotherapeutic agent, to prevent restenosis were 
performed by intravenous delivery (Sollott et al 1995). 
These studies showed that paclitaxel used for prevention 
of intimal hyperplasia can be administered at much lower International Journal of Nanomedicine 2007:2(2) 147
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concentrations than those needed for cancer therapy. 
Shortly following Sollott and colleagues’ study, locally-
administered paclitaxel to the arterial wall using a porous 
balloon catheter after angioplasty was examined (Axel 
et al 1997). Paclitaxel administered in this fashion con-
firmed previous results showing significant reduction in 
restenosis. Recently, clinical results of paclitaxel coated 
onto an angioplasty balloon and delivered locally showed 
significant promise. The results of these studies showed 
that local delivery of paclitaxel could inhibit neointimal 
growth without the need for a metallic stent (Scheller et 
al 2006). Paclitaxel is the active agent in Boston Scien-
tific’s Taxus® brand DES. The comparisons in terms of 
safety and efficacy between the Cypher® stent and Taxus® 
stent is outside the scope of this review. The readers are 
referred to some excellent reviews on the topic (Kittleson 
et al 2005; Perin 2005; Tung et al 2006a). 
In addition to sirolimus and paclitaxel, membrane sphin-
golipids, such as ceramide, that has been shown to enhance 
cellular apoptosis, has also been tested for treatment of 
restenosis (Charles et al 2000). When ceramide was coated 
onto an angioplasty balloon and tested in New Zealand white 
rabbit carotid artery after stretch injury, the results showed 
signiﬁ  cant inhibition of restenosis. 
The antiplatelet drug, cilostazol, was initially tested to 
treat restenosis with nonfavorable results, showing that it did 
not signiﬁ  cantly reduce restenosis after PTCA (Tsutsui et al 
1996). Subsequent studies did show a signiﬁ  cant difference 
in reduction of restenosis in patients taking cilostazol 
(Kunishima et al 1997; Take et al 1997). There has been 
several additional recent studies conﬁ  rming the results of 
Kunishima and colleagues and Take and colleagues indi-
cating that cilostazol does indeed have a positive effect on 
restenosis (Chen et al 2006). 
In addition to the above drugs that modulate various cell 
cycle stages, researchers have recently looked at a class of 
drugs known as bisophosphonates to reduce the inﬂ  ammatory 
response (Danenberg et al 2002, 2003). Clodronate, pamidro-
nate, alendronate and a novel bisphosphonate ISA-13-1 were 
all tested, and showed that systemic administration lowered 
local concentrations of inﬂ  ammatory mediators, thus reduc-
ing restenosis in a rat model (Danenberg et al 2003). 
Speciﬁ  c molecular targets have also been used for treat-
ment of restenosis. When PDGF-receptor speciﬁ  c molecules, 
tyrphostin, AG1295, and AGL-2043, were used to examine 
their effect on neointimal formation, they showed signiﬁ  cant 
inhibition of restenotic effects (Banai et al 1998, 2005). For a 
comprehensive review on PDGF receptor speciﬁ  c molecules 
see (Levitzki 2005). Table 1 below shows a summary of the 
drug classes used to treat restenosis. 
Gene therapy strategies
A variety of different gene targets have been used to 
treat restenosis. Since there have been numerous reviews 
written discussing the use of gene therapy for the treatment 
of restenosis and since this review is focusing on the 
nanoparticles role in treating restenosis, we will only brieﬂ  y 
touch on the subject of gene therapy to provide background 
information. For additional information, the readers are 
referred to (Rutanen et al 2002; Morishita 2004; Fishbein et al 
2005a, 2005c) for more thorough reviews of this topic. 
Restenosis gene therapy can be categorized by their 
method of action, and the cellular target (Rutanen et al 2002; 
Fishbein et al 2005a). The reduction of intimal hyperplasia 
has been the most investigated treatment option. Intimal 
hyperplasia can be reduced through three distinct modes 
of action. By transfecting cells with genes that encode 
for proteins known to destroy the cells as they enter the 
S-phase of the cell cycle such as thimidine kinase, cytosine 
deaminase and Fas ligand (FasL), intimal hyperplasia was 
inhibited (Guzman et al 1994; Ohno et al 1994; Ogata et al 
1996; Simari et al 1996; Harrell et al 1997; Mano et al 2000). 
Alternatively, the cell cycle can be arrested by certain gene 
products. These gene products take part in cellular regulation 
and, therefore, modulation of these genes would stop the 
cell cycle (Sriram and Patterson 2001; Bicknell et al 2003; 
Koledova and Khalil 2006). Genes that encode for kinases 
such as CDK2, CDC3, and cyclin B as well as CDK inhibi-
tors such as p21, p27, a fusion of p16 and p27, and p53 are 
all modulators of the cell cycle (Morishita et al 1994; Chen 
et al 1997; Yonemitsu et al 1998; Scheinman M 1999; Tanner 
et al 2000; Tsui et al 2001). hRAD 50 gene delivery effects 
p21 levels, subsequently inhibiting the cell cycle (Ahn et al 
2004). Alternatively, targeting of E2F a protein involved in 
the G1/S transition in cells has been approached through a 
Table 1 Drugs used in restenosis therapy
Action Drug(s)
Smooth muscle   Cytarabine, Doxorubicin, Vincristine, Dalteparin 
cell growth inhibition   sodium, Cyclosporine A, Colchicines, Etoposide, 
  Sirolimus, Paclitaxel, Ceramide
Antiplatelet Cilostazol
Inﬂ  ammatory   Clodronate, Pamidronate, Alendronate, ISA-13-1
response inhibition 
PDGF-receptor   AG-1295, AGL-2043
speciﬁ  cInternational Journal of Nanomedicine 2007:2(2) 148
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variety of different pathways. For example, with the use of 
nonphosphorylable retinoblastoma (Rb) gene, a protein that 
inhibits E2F, has been used to inhibit intimal hyperplasia 
(Chang et al 1995). An E2F decoy and a E2F-Rb chimera 
were used separately to successfully inhibit E2F levels 
(Morishita et al 1995; Kawauchi et al 2000; Wills et al 2001). 
Another pathway targeted for restenosis gene therapy is the 
protein kinase G (PKG) pathway. Truncated PKG gene has 
been used to increase PKG levels, a known inhibitor of neo-
intimal formation (Sinnaeve et al 2002). Similarly proliferat-
ing cell nuclear antigen (PCNA) ribozymes were shown to 
inhibit neointimal growth by inhibiting PCNA (Frimerman 
et al 1999). Other pathways targeted successfully include 
early growth response factor (Egr-1), dominant-negative 
H-ras, Gax homeobox, GATA homeobox and inteferon 
(INF)-β (Maillard et al 1997; Stephan et al 1997; Ueno et al 
1997; Mano et al 1999; Maillard et al 2000; Lowe et al 2001). 
Modulating local CO levels through iron metabolism with 
heme oxygenase-1 was found to inhibit intimal hyperplasia 
despite the exact lack of understanding of the mechanism 
(Tulis et al 2001; Kong et al 2004). 
Another approach for reducing restenosis via reduction 
of intimal hyperplasia would be to prevent the SMCs from 
migrating and forming a lesion on the arterial wall. Without 
the SMC movement, neointimal growth is not possible. 
It should be noted that these genes do not promote re-
endothelialization which is important in the long term health 
of the vessel. PDGF receptor β, a growth factor known to 
be involved in cell signaling and migration, has been shown 
to inhibit neointima formation (Cohen-Sacks et al 2002). 
Alternative approaches have encoded genes producing extra-
cellular matrix modifying proteases such as tissue inhibitor 
of metalloproteinases (TIMP-1) and plasminogen activator 
inhibitor (PAI-1) (Carmeliet et al 1997; Furman et al 2002; 
Turunen et al 2002, 2006; Puhakka et al 2005a, 2005b).
The use of gene therapy that affects multiple pathways 
simultaneously has also been investigated. These genes 
protect the endothelial cells and inhibit intimal hyperplasia. 
The use of vascular endothelial growth factor (VEGF), a 
well studied regulator of endothelial cell repair, has been 
used with some success (Asahara et al 1996; Laitinen et al 
1997; Van Belle et al 1997; Hiltunen et al 2000). Nitric 
oxide (NO) levels are known to play a role in the formation 
of intimal hyperplasia through a variety of different pathways 
(De Caterina et al 1995; Mooradian et al 1995). The synthesis 
of NO is regulated by a group of enzymes known as nitric 
oxide synthases (NOS). Two types of NOS have been used 
to reduce restenosis – inducible nitric oxide synthase (iNOS) 
and endothelial nitric oxide synthase (eNOS). NO is known 
to inhibit aggregation and adhesion of platelets, leukocytes, 
and to induce SMC apoptosis (Ross 1993). Local expression of 
nitric oxide synthase enzymes has been found to inhibit intimal 
hyperplasia (von der Leyen et al 1995; Chen et al 1998; Jans-
sens et al 1998; Shears et al 1998; Varenne et al 1998; Muhs 
et al 2003 ; Wang et al 2003; Kong et al 2004). 
The use of antithrombotic gene therapy has been investi-
gated to reduce restenosis. A number of different approaches 
have been tried. For instance, local transfection with a gene 
encoding thrombin inhibitor (hiridun) showed inhibition of 
restenosis (Rade et al 1996). Other successful approaches 
include transfecting a gene encoding TFPI, the target of the 
anti-thrombotic drug heparin to inhibit restenosis (Zoldhelyi 
et al 2001; Yin et al 2002). Prostacyclin synthase (PGIS) 
gene has been used directly and indirectly by modulating 
cyclooxygenase-1 (COX-1) production to inhibit restenosis 
(Wu 1997; Todaka et al 1999; Shyue et al 2001; Numaguchi 
et al 2004). COX-1 has also been shown to open the arterial 
wall, reducing pressure, and ultimately reducing the percentage 
of restenosis, though it did not directly effect intimal hyperplasia 
growth. In combination with other genes, this could be a 
promising target (Shyue et al 2001; Liu et al 2005). Table 2 
shows a summary of all of the gene therapy work completed 
for the treatment of restenosis.
Nanoparticulate delivery systems
Nanoparticulate delivery systems have been used to treat a 
variety of disease states. In restenosis treatment, both con-
ventional drugs- and gene-based medicines have been used in 
nanoparticle delivery to achieve desirable therapeutic results. 
There is a need for an alternative treatment since there are 
limitations to current therapies, such as in-stent restenosis, 
including the development for DES-related thrombosis and 
the high rate of restenosis with the use of bare metal stents and 
balloon angioplasty. A nanoparticle delivery system is well 
suited for the treatment of restenosis since local or targeted 
delivery can be achieved, lowering systemic toxicity, while 
reaching speciﬁ  c cell types in sufﬁ  cient concentrations for the 
necessary period of time. Biocompatible lipids and polymers 
also do not create an inﬂ  ammatory response. In the context 
of this article, liposomes, polymer-based nanoparticles, and 
micelles are considered as nanoparticulate carriers. The high 
shear pressure in the arterial blood supply leads to a very 
short residence time for the therapeutic agent at the target 
cells in the arterial wall. The use of nanoparticles allows for 
the rapid incorporation of the drug and gene into the cell, thus 
reducing the shear effects of the arterial pressure. Studies using International Journal of Nanomedicine 2007:2(2) 149
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ﬂ  orescent particles have shown a size dependency in arterial 
wall transfection using a SCIMED® REMEDY porous balloon 
catheter (Westedt et al 2002). Three particle sizes were tested 
and the data showed that the smallest size particles (~110 nm 
in diameter) had the greatest ﬂ  orescence intensity within the 
cell. Larger particles showed very little ﬂ  orescence due to 
short residence time on the arterial wall surface. Other studies 
showed an increase in inﬂ  ammatory responses with particles of 
5–10 μm in diameter and no therapeutic response, probably due 
to uptake by the macrophages and other immune cells rather 
than SMC or endothelial cells. (Gradus-Pizlo et al 1995; Dev 
et al 1997). Cells can incorporate particles varying from 
50–300 nm in diameter based upon a variety of different 
internalization pathways including nonspeciﬁ  c or receptor-
mediated endocytosis (Mukherjee et al 1997; Gruenberg 
2001; Pelkmans and Helenius 2002; Sieczkarski and Whit-
taker 2002; Mousavi et al 2004). Additionally, nanoparticles 
larger than 300 nm in diameter were found to accumulate in 
the liver, spleen and lung, rendering them unavailable for 
arterial delivery upon systemic administration (Wu and Wu 
1988). Other known factors for cellular uptake of nanoparticles 
include volume, concentration, infusion pressure, and the type of 
infusion balloon (Tahlil et al 1997; Westedt et al 2004). Increased 
delivery pressure and large volumes can cause an increase in the 
intimal thickening, while increased particle concentration leads 
to effective delivery (Westedt et al 2004). In addition, the use of 
cell speciﬁ  c surface modiﬁ  cations, can increase the residence 
time of the nanoparticles at the desired site.
Unlike in tumor mass, where the enhanced permeability 
and retention effect of the tumor vasculature plays a 
significant role in the accumulation of nanoparticles, the 
vascular endothelium is a much more difficult target to 
reach upon systemic delivery. The vascular flow rate is 
much higher in the arterial blood ﬂ  ow compared to the capil-
lary ﬂ  ow in tumors. However, some investigators, including 
Uwatoku and colleagues (2003) have hypothesized the 
presence of the enhanced permeability and retention ef-
fect in balloon injured arteries. However, it should be 
noted that the enhanced vascular permeability effects in 
restenotic vessels have not been confirmed by additional 
studies, especially in humans.
Pharmacokinetic studies were performed on the 
poly(L-lactide) nanoparticles to measure the local drug 
concentrations after site-speciﬁ  c arterial delivery (Fishbein 
et al 2001). Figure 2 shows a graph indicating two distinct 
ﬁ  rst order kinetic proﬁ  les. The initial accumulation of the 
nanoparticles on the intima, followed by subsequent slower 
accumulation in the media over time is observed. This bipha-
sic mechanism of particle internalization could be the cause 
of the two-phased drug pharmacokinetic proﬁ  le.
Illustrative examples 
of nanoparticle-based delivery 
in restenosis
Lipid nanoparticle-based drug delivery
Liposomes have been used to deliver a variety of drugs 
to the arterial endothelial cell wall. As previously out-
lined a number of drugs have been investigated to treat 
restenosis. Out of the drugs tested, only a subset has 
been administered through nanoparticle-based delivery 
systems. The bisphosphonate agent, clodronate, was 
delivered using a liposomal formulation consisting of 1:3 
distearoyl phosphatidylglycerol (DSPG), 1, 2-distearoyl-
sn-glycero-3-phosphocholine (DSPC) with an average 
particle size of 190 nm (Danenberg et al 2002). Results 
from this study showed that liposomal clodronate suc-
cessfully inhibited neointima growth in balloon-injured 
rabbit carotid artery after systemic administration. Other 
bisphosphonates including, pamidronate, alendronate and 
ISA-13-1 were tested in a similar liposomal formulation 
in a balloon-injured rat model (Danenberg et al 2003). To 
Table 2 Genes used in restenosis therapy
Cellular target  Action  Gene Product(s)
Intimal Hyperplasia  Antiproliferative (cytotoxic)  Thimidine kinase, Cytosine deaminase, FasL
  Antiproliferative (cytostatic)  cdc2, cdk2, cdc2, cyclin B, p21, hRAD 50, p27, p16–p27, p53,
    Nonphorphorylatable Rb, Rb/E2F chimera, E2F decoy, 
    Truncated PKG PCNA, Egr-1, Dominant-negative H-ras, 
    Gax homeobox, GATA homeobox
   IFN-β, Heme oxygenase-1, TIMP, PAI-1
Arterial Cytoprotection/  Re-endothelialization  VEGF
intimal hyperplasia  Mixed mechanism  eNOS, iNOS
Thrombosis  Antithrombotic  Hiridun, TFPI, Prostacyclin synthase, COX1International Journal of Nanomedicine 2007:2(2) 150
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deliver the liposomes to the target site, the researchers 
in these studies modified a piece of plastic tubing with a 
23-gauge catheter to perform local intraluminal delivery 
in addition to IV and subcutaneous administration. The 
results of this study showed that systemic administration 
not local administration leads to the greatest amount of 
reduction of neointimal growth, which is likely due to 
the mechanism of action of the drugs. These drugs act on 
macrophages, which are important in the inflammatory 
mechanism of restenosis (Danenberg et al 2002, 2003). 
Using liposomes to incorporate the hydrophilic bisphos-
phonates into macrophages is a novel approach for the 
compound class.
The use of Zn (II)-phthalocyanine, a photoactivatable 
agent, in a liposomal formulation was tested to inhibit SMC 
growth (Magaraggia et al 2006). This system was examined 
in cells and the result showed signiﬁ  cant apoptosis of vas-
cular SMC in vitro after a short irradiation time. Cellular 
uptake of oxidized low density lipoproteins (LDL) is an 
important step in the formation of atherosclerotic plaques 
and inﬂ  ammation. By engineering nanoparticles that block 
the LDL channels, researchers were able to inhibit LDL 
uptake, and show a reduction in inﬂ  ammatory responses 
(Chnari et al 2006). 
Polymeric nanoparticle-based 
drug delivery
A signiﬁ  cant amount of work has been ongoing and com-
pleted in the field of polymer-based nanoparticle drug 
delivery for the treatment of restenosis. The bisphosphinate 
agent, alendronate, was encapsulated in a poly(D,L-lactide-
co-glycolide) (PLGA) based nanoparticle system with an 
average size of 223 nm (Cohen-Sela et al 2006). The presence 
of calcium ions was found to be critical for the successful 
entrapment of the hydrophilic drug compound in PLGA 
matrices, alendronate in this formulation was delivered sub-
cutaneously and by intravenous administration. The results 
showed reduction in neointimal growth in a balloon injured 
rabbit model using both routes of administration (Cohen-Sela 
et al 2006). Interestingly, unlike with the liposomal formula-
tion, the subcutaneous PLGA nanoparticle formulation of 
alendronate showed a greater reduction in neointimal growth 
as compared to the intravenous formulation in a rabbit model 
(Danenberg et al 2002, 2003; Cohen-Sela et al 2006). 
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Figure 2 The effect of time on arterial AG-1295 concentrations following poly(L-lactic acid) nanoparticle-based delivery. Drug levels are depicted on a logarithmic scale. 
Initial washout period occurs within 24 hours of administration and the drug levels can be seen for up to 14 days. The drug concentrations were measured by a high 
performance liquid chromatography assay. Insert shows confocal images of rat carotid arteries following local delivery of Nile Red® dye- containing ﬂ  uorescent nanopar-
ticles. Images were acquired at 5 minutes (A), 90 minutes (B), 1 day (C), 7 days (D) and 14 days (E), as well as, after 15 minutes of intraluminal delivery and 6 hours after 
delivery (F). Discrete, granular, ﬂ  uorescent foci of nanoparticle aggregates are clearly observed in the image F. The notations L, M, N and A indicate lumen, media, neointima, 
and adventitia, respectively. Copyright © 2001. Reproduced from Fishbein I, Chorny M, Banai S, et al 2001. Formulation and delivery mode affect disposition and activity of 
tyrphostin-loaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol, 21:1434–39.International Journal of Nanomedicine 2007:2(2) 151
Nanoparticulate carriers for restenosis
Paclitaxel has been used in a number of nanopar-
ticle formulations for restenosis therapy. An alternative 
to paclitaxel-containing stent coating was developed by 
Bhargava and colleagues (2006). A cobalt chromium stent 
loaded with carbon-carbon nanoparticles was used in a stented 
injury swine model. In this study, three doses of paclitaxel 
in nanoparticle formulation showed inhibition of neointimal 
growth with less ﬁ  brosis and inﬂ  ammation when compared to 
the Cordis Cypher® stent. A comparison to the Taxus® DES 
would have been more relevant to see if the nanoparticle 
based therapy is better than the current therapy on the market. 
Albumin-based nanoparticles containing paclitaxel have also 
been used to prevent in-stent restenosis (Kolodgie et al 2002). 
The paclitaxel concentrations was lower than typically used 
for chemotherapy in a denuded stented rabbit model. The data 
indicated that after 28 days, neointimal growth was inhibited 
with a single dose locally administered to the iliac bifurcation, 
while a second systemically administered dose was needed 
to see the effects prolonged out to 90 days. Doxorubicin an 
anthracycline anticancer agent, and paclitaxel were used in 
a tissue factor targeted lipid/perﬂ  orocarbon nano-emulsion 
to target vascular SMC proliferation in vitro using porcine 
SMC (Lanza et al 2002). Targeted nano-emulsion had 
greater efﬁ  cacy in preventing SMC growth in these studies. 
The formulation containing doxorubicin and paclitaxel had 
a greater effect that single drug probably due to synergistic 
pro-apoptotic activity of these chemotherapeutic agents. 
Doxorubicin has also been used in a polymeric micelle 
consisting of NK911, a self assembling block co-polymer, 
to treat restenosis in a balloon-injured rat carotid artery 
model (Uwatoku et al 2003). Results from this study showed 
that doxorubicin encapsulated within NK911 permeated 
the arterial wall and prevented neointimal growth. The 
authors claim that the formulation was able to target the 
damaged endothelium due to a local enhanced permeability 
and retention effect in the arterial wall. This effect has not 
been conﬁ  rmed in any other reports. The small size (40 nm) 
of the delivery system could lead to an increased uptake 
in a damaged arterial wall after systemic administration. 
Another antiproliferative agent formulated in a PLGA based 
nanoparticle system was U-86, a 2-aminochromone, which is 
an experimental anti-proliferative compound (Labhasetwar 
et al 1998). A number of different surface modiﬁ  cations 
strategies to alter the charge of the nanoparticle system and 
to promote adhesion to the cells were tested. The results of 
this study showed that surface modiﬁ  cation with a cationic 
surfactant, didodecyldimethylammonium bromide (DMAB), 
was most beneﬁ  cial in producing a 7–10 fold increase in 
arterial drug levels due to an increase in the residence time 
of the nanoparticles on the endothelial surface. 
In addition to the Bisphosphonates and anti-cancer 
drugs, tyrphostins have been tested in a variety of differ-
ent nanoparticle systems for restenosis. Poly(L-lactic acid) 
(PLA) nanoparticles have been tested in a balloon-injured 
swine model (Banai et al 1998). Results showed that infu-
sion catheter local delivery inhibited SMC growth. Simi-
larly tyrphostin AG-1295 was encapsulated in a PLA-based 
nanoparticle and was administered locally using a porous 
balloon to a rat with denuded carotid artery (Fishbein 
et al 2000). Results were similar to previous work showing 
inhibition of SMC growth. In this formulation, the particle 
size was modulated and the results showed that the smaller 
particle sized nano-delivery systems were more efﬁ  cacious. 
A related tyrphostin AGL-2043 was tested in a similar PLA-
based nanoparticle system in balloon-injured rat carotid 
arteries and stented porcine arteries (Banai et al 2005). Re-
sults from this study indicated the nano-encapsulated drug 
was more successful in inhibiting restenosis in both animal 
models. Table 3 summarizes the results obtained from vari-
ous studies of drug-encapsulated nanoparticle systems for 
restenosis therapy.
Lipid nanoparticle-based gene delivery 
A significant amount of work has been accomplished in 
the field of nonviral nanoparticle-based gene delivery for 
restenosis. Table 4 is a summary of the studies performed 
to date. Most of the work on nonviral transfection has 
been performed with commercially-available cationic 
lipid transfection reagents such as Lipofectamine® or 
Lipofectamine Plus®. The use of Lipofectamine® or 
Lipofectamine Plus® in delivery of genes is not a clinically 
viable option due to the known toxicity of the cationic 
lipid transfection reagents (Armeanu et al 2000). Lipo-
fectamine Plus® has been used in local delivery of pro-
liferating cell nuclear antigen hammerhead ribozyme in a 
stented porcine model (Frimerman et al 1999). Results of 
this study showed that the ribozyme successfully inhibited 
intimal hyperplasia in the stented model. Figure 3 shows 
a cross section of the stented porcine arteries without 
treatment, with administration of a nonspecific ribozyme, 
and administration of PCNA speciﬁ  c ribozyme in nanoparticle 
formulations. The gene for eNOS was transfected in a 
canine ex-vivo saphenous vein graft using Lipofectamine 
Plus® (Kalra et al 2000). In this study, the gene was trans-
fected through the intimal and adventetial routes. The 
results indicated that intimal transfection did not show International Journal of Nanomedicine 2007:2(2) 152
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an efficient gene transfection, whereas the veins treated 
through the adventitia did show efficient transfection. 
The gene encoding for prostacyclin synthase (PGIS) 
was delivered with Lipofectamine® into balloon-injured 
New Zealand white rabbits (Numaguchi et al 2004). A 
stent was deployed at the site of injury and a Dispatch® 
catheter was used for delivery of the nanoparticulate 
plasmid DNA formulation locally. The data from this 
study showed that PGIS prevented vascular SMC growth, 
stimulated re-endothelialization, and prevented neointi-
mal formation. 
Using nonliposomal transfection reagent FuGENE 6 
(Boehringer Mannheim) hRAD50 encoding plasmid DNA 
was delivered to stented pigs using the Dispatch® catheter 
(Ahn et al 2004). From this study, short term inhibition of 
neointimal formation was observed. However, long-term 
investigations are needed to determine the effect RAD50 
mediated re-endothelialization. 
The use of plasmid DNA encoding for inducible 
and endothelial nitric oxide synthase (iNOS and eNOS, 
respectively) has been studied extensively in other 
types of cationic liposomes. Using Lipofectamine® as 
a transfection reagent, endothelial nitric oxide synthase 
(eNOS) expressing plasmid DNA was administered to 
HUVEC cells to measure the effect of various inhibitors 
and inducers on eNOS production (Qiao et al 2006). 
The conclusion from this study was that peripheral 
eNOS side effects should be emphasized during clinical 
administration (Qiao et al 2006). In another study, the 
researchers examined local iNOS plasmid delivery to 
an injured mini pig femoral and coronary artery model (Muhs 
et al 2003). Administration of the complexed plasmid 
was performed using an Infiltrator® infusion catheter, 
the animals were stented to produce the injury. The 
lipid-DNA complex (lipoplex) contained monocationic 
lipid 3β-(N,N′-di-methylaminoethane)-carbamoylcholes-
terol (DAC) at 30% (w/w) and dioleoyl phosphatidyletha-
nolamine (DOPE) at 70% (w/w). When administered to the 
injured model, the results indicated that despite the break-
down of excess NO in the bloodstream by hemoglobin, 
significant reduction of neointimal growth was observed 
with this DNA delivery system. Using a similar liposomal 
system, Pfiffer and colleagues (2006) used an Infiltrator® 
catheter to administer iNOS expressing plasmid DNA in a 
foxhound dog model after an arterial graft. In this study, 
the intimal hyperplasia was inhibited for up to 6 months 
with a single local plasmid DNA administration. In vivo 
studies of eNOS plasmid DNA formulated in cationic 
lipid 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl) 
imidazolinium chloride (DOTIM) and cholesterol in a 
1:1 weight ratio, was performed (Iwata et al 2000). 
Using a Stauffland rabbit model, an in-situ transfected 
carotid artery was grafted into the animal. The results 
indicated that eNOS transfected in this manner reduced 
Figure 3 Low magniﬁ  cation (10x) images of porcine arteries 4 weeks after stent implantation. The images represent stent only (A), untreated tissue as a negative control 
(B), and delivery of PCN1 ribozyme therapeutic agent (C). Panels A and B show well-deﬁ  ned intimal hyperplasia, whereas panel C shows a signiﬁ  cantly lesser amount of 
neointimal growth. Lower panel images correspond to high magniﬁ  cation of the above. No histological evidence of tissue inﬂ  ammation is seen. Copyright © 1999. Repro-
duced from Frimerman A, Welch PJ, Jin X, et al 1999. “Chimeric DNA-RNA hammerhead ribozyme to proliferating cell nuclear antigen reduces stent-induced stenosis in a 
porcine coronary model.” Circulation, 99:697–703.International Journal of Nanomedicine 2007:2(2) 156
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neointimal formation with effects lasting up to 21 days 
after transfection (Iwata et al 2000). The same formulation 
was also used in a heart transplanted rabbit with similar 
results (Iwata et al 2001). 
Other genes that have been delivered to the arterial wall 
with cationic liposomes include chloramphenicol acetyl 
transferase (CAT) gene. CAT gene was delivered with two dif-
ferent cationic lipid formulations – (±)-N-(2-Hydroxyethyl)-N, 
N-dimethyl-2,3-bis(tetradecyloxy)-1-propanaminium bro-
mide (DMRIE)/DOPE and (±)-N-(3-aminopropyl)-N,N-
dimethyl-2, 3-bis(dodecyloxy)-1-propanaminium bromide) 
(GAP-DLRIE)/DOPE – in balloon-injured Yorkshire pigs 
using a catheter for local delivery (Stephan et al 1996). 
The results of this study indicated that GAP-DLRIE/DOPE 
liposomal system was more efﬁ  cient in transfecting the 
artery as compared to the DMRIE/DOPE formulation. 
The cationic lipid (DOCSPER) (1,3-dioleoyloxy-2-(N5-
carbamoyl-spermine)-propane) was used to transfer C-type 
naturetic peptide (CNP) gene in a pig femoral artery model 
(Pelisek et al 2006). Brieﬂ  y, the CNP and CNP gene were 
delivered to the artery and the results showed that a single 
CNP gene administration inhibited neointima formation better 
than systemic administration of the peptide. Similar results 
were observed in a porcine renal model (Kuhnl et al 2005). 
VEGF gene delivery was performed in human patients 
using a cationic mixture of DOTMA and DOPE as part of 
a clinical trial to induce collateral circulation following 
myocardial ischemia (Hedman et al 2003). Gene transfer 
was performed prior to stenting using a Dispatch® catheter 
for local tissue delivery. From this study, the results showed 
that cationic lipid transfer of VEGF did not affect the in-
cidence of restenosis. When VEGF was transferred via a 
viral vector, myocardial perfusion was increased. A greater 
transfection efﬁ  ciently produced by the viral vector was likely 
the cause for the difference in the observed activity. The 
gene for TIMP-1 was used in a α5β1 targeted Lipofectin® 
nanoparticulate delivery system (Meng et al 2006). From 
this study, it was observed that this type of delivery system 
was effective in inhibiting neointimal hyperplasia for up to 
28 days in a balloon-injured rat model. 
Viral-mimicking liposomes have been extensively used to 
deliver genes to the arterial wall. Brieﬂ  y, in this case, a liposome 
is made and then bound to the envelop protein of a virus, such as 
the hemaglutin virus of Japan (HJV). This formulation strategy 
allows for better transfection of the encapsulated gene into the 
cell. In one example, E2F oligonucleotide decoy was adminis-
tered using a viral liposome system. Artiﬁ  cial HJV-liposomes 
were used to deliver E2F decoy ex-vivo in both a murine and a 
primate cardiac transplant model to inhibit neointimal growth 
(Kawauchi et al 2000). The artiﬁ  cial viral liposomes were shown 
to have increased transfection for oligonucleotides. Additionally, 
the results showed that SMC growth was inhibited resulting 
form the inhibition of neointima formation. Other investigators 
have used HJV-liposome delivered E2F decoy in a denuded rat 
carotid artery model showing inhibition of the neointima for 
up to 8 weeks following administration (Morishita et al 1995). 
Other nucleic acid therapies delivered with the HJV-liposome 
delivery system include wild-type p53, tissue factor pathway 
inhibitor gene (TFPI), and PGIS (Yonemitsu et al 1998; Todaka 
et al 1999; Yin et al 2002). Wild-type p53 was delivered to white 
rabbits using a double lumen catheter to locally administer and 
transfect the therapeutic gene. Results indicated that p53 gene 
transfer inhibited neointimal formation, with and without apop-
totic stimuli (Yonemitsu et al 1998). White rabbits were also used 
as a model to test TFPI transfection by local administration the 
encapsulated plasmid (Yin et al 2002). The results of the study 
showed that TFPI successfully inhibits neointimal growth up 
to 4 weeks after administration. PGIS was delivered in a HJV-
liposome in a denuded rat carotid model (Todaka et al 1999). 
An infusion catheter was used to deliver the encapsulated gene; 
results indicated that neointima growth was inhibited. 
Polymeric nanoparticle-based gene delivery
Unlike lipid-based delivery, there are a small number of 
studies performed with polymer based nano-delivery systems 
to deliver genes to the arterial wall. Depending on the type 
of polymer used, these nanoparticulate delivery systems 
are able to modify the release of the genes, while sharing 
similar transfection efﬁ  cacy as lipid nano-systems. For 
instance, PLGA-based nanoparticles were used to deliver 
PDGF receptor β antisense RNAi to an injured rat carotid 
artery (Cohen-Sacks et al 2002). The delivery system was 
made to release over a period of one month allowing for 
a lower dose of the therapeutic agent to be administered 
over a long period of time. From these studies, inhibition 
of the neointima growth was observed for a period of one 
month. When the lowest dose was used, some inhibition 
was observed without drug encapsulation. However, as the 
dose was increased, there no inhibition when the antisense 
was not encapsulated. Another delivery system used in the 
treatment of restenosis was a PEI based delivery system for 
monocyte chemoattractant protein 1 (MCP-1) (Lenter et al 
2004). In addition to the PEI formulation, alternative formu-
lations tested included combinations with the surface active 
peptide mellatin and PEG. The formulations were tested in 
a variety of different smooth muscle and endothelial cells, International Journal of Nanomedicine 2007:2(2) 157
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showing that delivery systems coated with PEG exhibited 
less toxicity and an increase in activity of the formulations 
when combined with mellatin.
Other therapeutic delivery systems
The use of nucleic acids therapies such as ribozymes and 
DNAzymes have also been investigated in the field of 
restenosis. DNAzymes were targeted against transcription 
factor EGR-1 in a stented porcine model (Lowe et al 2001). 
Inhibition of the neo-intimal growth was observed in this ﬁ  rst 
study of DNAzymes delivery to the arterial wall. 
Surface functionalization 
of nanoparticles for targeting 
restenosis
Damaged endothelial cells within the coronary artery are 
difﬁ  cult drug targets for site-speciﬁ  c localization of the 
nanoparticles upon systemic administration. In addition, 
many of the drugs and genes used for the prevention and 
treatment of intimal hyperplasia are known to produce 
cytotoxic effects within the body. Systemic administration 
of these drugs and genes would cause unwanted effects. In 
order to enhance site-speciﬁ  city, there are several strategies 
that have been tried to functionalize the nanoparticle surface 
in order to achieve better localization of the delivery systems 
at the target site.
There are very few reported studies on active targeting 
of damaged endothelial cells for the treatment of restenosis. 
A common targeting moiety for endothelial cells is the 
argentine-lysine-aspartic acid (RGD) tripeptide sequence 
that is speciﬁ  c to the alpha(v)-beta(3) integrins present 
abundantly on sprouting endothelial cells and certain tumor 
types (Dijkgraaf et al 2007). Another alpha(v)-beta(3) inte-
grin speciﬁ  c peptide sequence is PHSRN (Mardilovich et 
al 2006). Other endothelial cell targeting moieties based on 
an amino acid sequence are YIGSR, and HWGF (Turunen 
et al 2002; Jun and West 2005). VCAM-1 is a potential 
biomarker present on atherosclerotic surface. By targeting 
that biomarker, the delivery system would be highly local-
ized to the area of interest (Kelly et al 2006). A nanoparticle 
delivery system modiﬁ  ed with VINP28, a peptide speciﬁ  c 
to VCAM-1, on the surface was shown to have preferential 
afﬁ  nity to the endothelial cells as compared to macrophages 
or SMCs. Weissleder and colleagues (2005) produced a 
library of small molecule endothelial cell-speciﬁ  c target-
ing moieties. These targeting moieties have not yet been 
used in any restenosis studies. The use of PLGA-based 
nanoparticles functionalized with an ICAM antibody was 
recently shown to successfully target the endothelial cells 
in vitro (Muro et al 2006). 
Alternative localized delivery
Functionalization of nanoparticles can target speciﬁ  c cell 
types. If a broad area within the vessel is the target there are 
other strategies available. The use of local administration 
using an infusion catheter as previously described with a 
Dispatch®, Inﬁ  ltrator®, or other cardiac infusion catheters is 
one way to achieve local high levels of the therapeutic agent 
(Tahlil et al 1997; Panyam et al 2002). Local administration 
is also achieved through the use of drug and/or gene eluting 
stents such as the Cypher® and Taxus® stents (Fishbein et al 
2005a, 2005b; Kittleson et al 2005; Perin 2005; Tung et al 
2006b). Other drug-coated stents using different designs, 
such as biodegradable stents, as well as other systems are 
being evaluated in preclinical and clinical studies (Eisenberg 
and Konnyu 2006). Ex vivo application of the drug or gene 
in the cells is also another possible way to reduce systemic 
2fects of the administered drug. However, clinical application 
of the ex vivo approach will be quite limited. 
Conclusion and future outlook
There is a need to develop an alterative to stents and drug-elut-
ing stents for the treatment of coronary restenosis. In this review 
paper, we have evaluated the current research in the ﬁ  eld of 
nanoparticulate carriers for delivery of drugs and genes. Future 
work should focus on creating novel delivery systems that have 
less cytotoxic effects. Much of the liposomal work done to 
date, uses Lipofectamine® as the transfection agent. While this 
transfection reagent works well in nonclinical settings, it has 
shown to exhibit signiﬁ  cant toxicity in porcine arteries upon 
systemic administration (Armeanu et al 2000). Few studies have 
utilized the advances in nanoparticle targeting for treatment of 
restenosis. The cytostatic drugs currently being used may not be 
the best option for the treatment of this disorder, as they do not 
promote the growth of the endothelium. The work performed 
in the ﬁ  eld of active targeting has produced a number of cell-
speciﬁ  c targeting ligands that would enhance the delivery and 
retention of the nanoparticles to the restenotic lesion, resulting 
in an increase in the efﬁ  cacy of the therapeutic agent. Future 
studies should focus on creating biocompatible nanoparticles 
with targeting moieties to allow for increased tissue-speciﬁ  c 
delivery and cellular uptake with limited toxicity upon systemic 
administration. Gelatin-based materials, for instance, may 
be particularly well suited for this application, since there is 
abundance of collagen at the site of the lesion. Gelatin-based 
delivery systems also do not induce any inﬂ  ammatory effect. International Journal of Nanomedicine 2007:2(2) 158
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The key to developing a successful therapy will be to promote 
re-endothelialization, while inhibiting any SMC growth, or 
vascular remodeling. Ideally, the therapy will be able to be 
given in a noninvasive manner or in conjunction with the 
initial clearing of the atherosclerotic plaque using an infusion 
balloon catheter. With recent observations of thrombosis upon 
long-term implantantation of the DES, it is clear that alterna-
tive therapeutic strategies are needed for effective treatment 
of coronary restenosis. This review, hopefully, will provide an 
impetus for further research in this area and, especially promote 
the development of nanoparticulate delivery systems for both 
drug and gene therapy of this disease.
References
Ahn YK, Kook H, Jeong MH, et al. 2004. Local RAD50 gene delivery 
induces regression of preformed porcine coronary in-stent neointimal 
hyperplasia. The Journal of Gene Medicine, 6(1):93–104.
Armeanu S, Pelisek J, Krausz E, et al. 2000. Optimization of nonviral gene 
transfer of vascular smooth muscle cells in vitro and in vivo. Molecular 
Therapy,1(4):366–375.
Asahara T, Chen D, Tsurumi Y, et al. 1996. Accelerated restitution of endo-
thelial integrity and endothelium-dependent function after phVEGF165 
gene transfer. Circulation, 94(12):3291–3302.
Axel DI, Kunert W, Goggelmann C, et al. 1997. Paclitaxel inhibits arterial 
smooth muscle cell proliferation and migration in vitro and in vivo 
using local drug delivery. Circulation, 96(2):636–645.
Banai S, Chorny M, Gertz SD, et al. 2005. Locally delivered nanoencapsu-
lated tyrphostin (AGL-2043) reduces neointima formation in balloon-
injured rat carotid and stented porcine coronary arteries. Biomaterials, 
26(4):451–461.
Banai S, Wolf Y, Golomb G, et al. 1998. PDGF-receptor tyrosine kinase 
blocker AG1295 selectively attenuates smooth muscle cell growth 
in vitro and reduces neointimal formation after balloon angioplasty in 
swine. Circulation, 97(19):1960–1969.
Bhargava B, Reddy NK, Karthikeyan G, et al. 2006. A novel paclitaxel-
eluting porous carbon-carbon nanoparticle coated, nonpolymeric 
cobalt-chromium stent: Evaluation in a porcine model. Catheterization 
and Cardiovascular Interventions, 67(5):698–702.
Bicknell KA, Surry EL, Brooks G. 2003. Targeting the cell cycle machinery 
for the treatment of cardiovascular disease. J Pharm Pharmacol, 
55(5):571–91.
Bose D, Eggebrecht H, Erbel R. 2006. Absorbable metal stent in human 
coronary arteries: imaging with intravascular ultrasound. Heart, 
92(7):892.
Braun-Dullaeus RC, Mann MJ, Dzau VJ. 1998. Cell cycle progression: 
new therapeutic target for vascular proliferative disease. Circulation, 
98(1):82–9.
Carmeliet P, Moons L, Lijnen R, et al. 1997. Inhibitory role of plasminogen 
activator inhibitor-1 in arterial wound healing and neointima forma-
tion : A gene targeting and gene transfer study in mice. Circulation, 
96(9):3180–3191.
Chang MW, Barr E, Seltzer J, et al. 1995. Cytostatic gene therapy for 
vascular proliferative disorders with a constitutively active form of the 
retinoblastoma gene product. Science, 267(5197):518–22.
Charles R, Sandirasegarane L, Yun J, et al. 2000. Ceramide-coated balloon 
catheters limit neointimal hyperplasia after stretch injury in carotid 
arteries. Circ Res, 87(4):282–288.
Chen D, Krasinski K, Chen D, et al. 1997. Downregulation of cyclin-
dependent kinase 2 activity and cyclin a promoter activity in vascular 
smooth muscle cells by p27KIP1, an inhibitor of neointima formation 
in the rat carotid artery. J. Clin. Invest, 99(10):2334–2341.
Chen L, Daum G, Forough R, et al. 1998. Overexpression of human endo-
thelial nitric oxide synthase in rat vascular smooth muscle cells and in 
balloon-injured carotid artery. Circ Res, 82(8):862–870.
Chen YD, Lu YL, Jin ZN, et al. 2006. A prospective randomized antiplatelet 
trial of cilostazol versus clopidogrel in patients with bare metal stent. 
Chinese Medical Journal, 119(5):360–366. 
Chnari E, Nikitczuk JS, Wang J, et al. 2006. Engineered polymeric 
nanoparticles for receptor-targeted blockage of oxidized low density 
lipoprotein uptake and atherogenesis in macrophages. Biomacromol-
ecules, 7(6):1796–1805.
Cohen-Sacks H, Najajreh Y, Tchaikovski V, et al. 2002. Novel PDGFbetaR 
antisense encapsulated in polymeric nanospheres for the treatment of 
restenosis. Gene Therapy, 9(23):1607–16.
Cohen-Sela E, Rosenzweig O, Gao J, et al. 2006. Alendronate-loaded 
nanoparticles deplete monocytes and attenuate restenosis. Journal of 
Controlled Release, 113(1):23–30.
Costa MA, Simon DI. 2005. Molecular basis of restenosis and drug-eluting 
stents. Circulation, 111(17):2257–2273.
Danenberg HD, Fishbein I, Epstein H, et al. 2003. Systemic depletion 
of macrophages by liposomal bisphosphonates reduces neointimal 
formation following balloon-injury in the rat carotid artery. Journal of 
Cardiovascular Pharmacology, 42(5):671–679.
Danenberg HD, Fishbein I, Gao J, et al. 2002. Macrophage depletion by 
clodronate-containing liposomes reduces neointimal formation after 
balloon injury in rats and rabbits. Circulation, 106(5):599–605.
De Caterina R, Libby P, Peng HB, et al. 1995. Nitric oxide decreases 
cytokine-induced endothelial activation. Nitric oxide selectively reduces 
endothelial expression of adhesion molecules and proinﬂ  ammatory 
cytokines. J Clin Invest, 96(1):60–68.
Degertekin M, Regar E, Tanabe K, et al. 2003. Sirolimus-eluting stent for 
treatment of complex in-stent restenosis: The ﬁ  rst clinical experience. 
Journal of the American College of Cardiology, 41(2):184–189.
Dev V, Eigler N, Fishbein MC, et al. 1997. Sustained local drug delivery to 
the arterial wall via biodegradable microspheres. Catheterization and 
Cardiovascular Diagnosis, 41(3):324–332.
Di Mario C, Grifﬁ  ths HUW, Goktekin O, et al. 2004. Drug-Eluting Bioabsorbable 
magnesium stent. Journal of Interventional Cardiology, 17(6):391–395.
Dijkgraaf I, Kruijtzer JA, Liu S, et al. 2007. Improved targeting of the αvβ 
3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol 
Imaging, 34(2):267–273.
Eisenberg MJ, Konnyu KJ. 2006. Review of randomized clinical trials 
of drug-eluting stents for the prevention of in-stent restenosis. The 
American Journal of Cardiology, 98(3):375–382.
Elezi S, Kastrati A, Hadamitzky M, et al. 1999. Clinical and angiographic 
follow-up after balloon angioplasty with provisional stenting for 
coronary in-stent restenosis. Catheterization and Cardiovascular 
Interventions, 48(2):151–156.
Farb A, Kolodgie FD, Hwang JY, et al. 2004. Extracellular ma-
trix changes in stented human coronary arteries. Circulation, 
110(8):940–947.
Farb A, Weber DK, Kolodgie FD, et al. 2002. Morphological predic-
tors of restenosis after coronary stenting in humans. Circulation, 
105(25):2974–2980.
Fishbein I, Chorny M, Banai S, et al. 2001. Formulation and delivery mode 
affect disposition and activity of tyrphostin-loaded nanoparticles in the 
rat carotid model. Arterioscler Thromb Vasc Biol, 21(9):1434–1439.
Fishbein I, Chorny M, Rabinovich L, et al. 2000. Nanoparticulate delivery 
system of a tyrphostin for the treatment of restenosis. Journal of Con-
trolled Release, 65(1–2):221–229.
Fishbein I, Perlstein I, Levy R. 2005a. Gene therapy for in-stent restenosis. 
polymeric gene delivery: principles and applications. M Amiji. New 
York, CRC Press.
Fishbein I, Stachelek SJ, Connolly JM, et al. 2005b. Site speciﬁ  c gene deliv-
ery in the cardiovascular system. J Control Release, 109(1–3):37–48.
Fishbein I, Stachelek SJ, Connolly JM, et al. 2005c. Site speciﬁ  c gene 
delivery in the cardiovascular system. Journal of Controlled Release, 
109(1–3):37–48.International Journal of Nanomedicine 2007:2(2) 159
Nanoparticulate carriers for restenosis
Frimerman A, Welch PJ, Jin X, et al. 1999. Chimeric DNA-RNA hammer-
head ribozyme to proliferating cell nuclear antigen reduces stent-induced 
stenosis in a porcine coronary model. Circulation, 99(5):697–703.
Furman C, Luo Z, Walsh K, et al. 2002. Systemic tissue inhibitor of metal-
loproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-
injured rat carotid artery. FEBS Letters, 531(2):122–126.
Gaspardone A, Versaci F. 2005. Coronary stenting and inﬂ  ammation. Am 
J Cardiol, 96(12A):65L-70L.
Goldberg SL, Loussararian A, De Gregorio J, et al. 2001. Predictors of 
diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol, 
37(4):1019–25.
Gradus-Pizlo I, Wilensky RL, March KL, et al. 1995. Local delivery of 
biodegradable microparticles containing colchicine or a colchicine 
analogue: Effects on restenosis and implications for catheter-based 
drug delivery. Journal of the American College of Cardiology, 
26(6):1549–1557.
Gruenberg J. 2001. The endocytic pathway: a mosaic of domains. Nature 
Reviews. Molecular Cell Biology, 2(10):721–730.
Guzman RJ, Hirschowitz EA, Brody SL, et al. 1994. In vivo suppression 
of injury-induced vascular smooth muscle cell accumulation using 
adenovirus-mediated transfer of the herpes simplex virus thymidine 
kinase gene. PNAS, 91(22):10732–10736.
Harrell RL, Rajanayagam MAS, Doanes AM, et al. 1997. Inhibition of 
vascular smooth muscle cell proliferation and neointimal accumulation 
by adenovirus-mediated gene transfer of cytosine deaminase. Circula-
tion, 96(2):621–627.
Hedman M, Hartikainen J, Syvanne M, et al. 2003. Safety and feasibil-
ity of catheter-based local intracoronary vascular endothelial growth 
factor gene transfer in the prevention of postangioplasty and in-stent 
restenosis and in the treatment of chronic myocardial ischemia: 
Phase II results of the kuopio angiogenesis trial (KAT). Circulation, 
107(21):2677–2683.
Hiltunen MO, Laitinen M, Turunen MP, et al. 2000. Intravascular adeno-
virus-mediated vegf-c gene transfer reduces neointima formation in 
balloon-denuded rabbit aorta. Circulation, 102(18):2262–2268.
Hoffmann R, Mintz GS, Dussaillant GR, et al. 1996. Patterns and mecha-
nisms of in-stent restenosis. A serial intravascular ultrasound study. 
Circulation, 94(6):1247–54.
Horvath C, Welt FGP, Nedelman M, et al. 2002. Targeting CCR2 or 
CD18 inhibits experimental in-stent restenosis in primates: Inhibitory 
potential depends on type of injury and leukocytes targeted. Circ Res, 
90(4):488–494.
Iwata A, Sai S, Moore M, et al. 2000. Gene therapy of transplant ar-
teriopathy by liposome-mediated transfection of endothelial nitric 
oxide synthase. The Journal of Heart and Lung Transplantation, 
19(11):1017–1028.
Iwata A, Sai S, Nitta Y, et al. 2001. Liposome-mediated gene transfec-
tion of endothelial nitric oxide synthase reduces endothelial activa-
tion and leukocyte inﬁ  ltration in transplanted hearts. Circulation, 
103(22):2753–2759.
Janssens S, Flaherty D, Nong Z, et al. 1998. Human endothelial nitric oxide 
synthase gene transfer inhibits vascular smooth muscle cell prolifera-
tion and neointima formation after balloon injury in rats. Circulation, 
97(13):1274–1281.
Jun HW, West JL. 2005. Endothelialization of microporous YIGSR/PEG-
modiﬁ  ed polyurethaneurea. Tissue Engineering, 11(7–8):1133–1140.
Kalra M, Jost CJ, Severson SR, et al. 2000. Adventitial versus intimal 
liposome-mediated ex vivo transfection of canine saphenous vein 
grafts with endothelial nitric oxide synthase gene. Journal of Vascular 
Surgery, 32(6):1190–1200.
Kandzari DE, Roe MT, Ohman EM, et al. 2005. Frequency, predictors, and 
outcomes of drug-eluting stent utilization in patients with high-risk 
Non-ST-Segment elevation acute coronary syndromes. The American 
Journal of Cardiology, 96(6):750–755.
Kastrati A, Mehilli J, Dirschinger J, et al. 2001. Restenosis after coronary 
placement of various stent types. The American Journal of Cardiol-
ogy, 87(1):34–39.
Kawauchi M, Suzuki JI, Morishita R, et al. 2000. Gene therapy for attenuat-
ing cardiac allograft arteriopathy using ex vivo E2F Decoy transfection 
by HVJ-AVE-Liposome method in mice and nonhuman primates. Circ 
Res, 87(11):1063–1068.
Kelly K, Nahrendorf M, Yu A, et al. 2006. In vivo phage display selection 
yields atherosclerotic plaque targeted peptides for imaging. Molecular 
Imaging and Biology, 8(4):201–207.
Kittleson MM, Needham DM, Kim SJ, et al. 2005. The efﬁ  cacy of sirolimus- 
and paclitaxel-eluting stents: a meta-analysis of randomized controlled 
trials. Can J Cardiol, 21(7):581–7.
Koledova VV, Khalil RA. 2006. Ca2+, Calmodulin, and cyclins in vascular 
smooth muscle cell cycle. Circ Res, 98(10):1240–1243.
Kollum M, Farb A, Schreiber R, et al. 2005. Particle debris from a 
nanoporous stent coating obscures potential antiproliferative effects of 
tacrolimus-eluting stents in a porcine model of restenosis. Catheteriza-
tion and Cardiovascular Interventions, 64(1):85–90.
Kolodgie FD, John M, Khurana C, et al. 2002. Sustained reduction of 
in-stent neointimal growth with the use of a novel systemic nanoparticle 
paclitaxel. Circulation, 106(10):1195–1198.
Kong D, Melo LG, Mangi AA, et al. 2004. Enhanced inhibition of neointimal 
hyperplasia by genetically engineered endothelial progenitor cells. 
Circulation, 109(14):1769–1775.
Kornowski R, Hong MK, Tio FO, et al. 1998. In-stent restenosis: 
contributions of inﬂ  ammatory responses and arterial injury to neointimal 
hyperplasia. J Am Coll Cardiol, 31(1):224–30.
Kuhnl A, Pelisek J, Tian W, et al. 2005. C-type natriuretic peptide inhibits con-
strictive remodeling without compromising re-endothelialization in balloon-
dilated renal arteries. Journal of Endovascular Therapy, 12(2):171–182.
Kunishima T, Musha H, Eto F, et al. 1997. A randomized trial of aspirin 
versus cilostazol therapy after successful coronary stent implantation. 
Clinical Therapeutics, 19(5):1058–1066.
Labhasetwar V, Song C, Humphrey W, et al. 1998. Arterial uptake of 
biodegradable nanoparticles: Effect of surface modiﬁ  cations. Journal 
of Pharmaceutical Sciences, 87(10):1229–1234.
Laitinen M, Zachary I, Breier G, et al. 1997. VEGF gene transfer reduces 
intimal thickening via increased production of nitric oxide in carotid 
arteries. Hum Gene Ther, 10(8):1737–44.
Lanza GM, Yu X, Winter PM, et al. 2002. Targeted antiproliferative drug 
delivery to vascular smooth muscle cells with a magnetic resonance 
imaging nanoparticle contrast agent: Implications for rational therapy 
of restenosis. Circulation, 106(22):2842–2847.
Lenter M, Garidel P, Pelisek J, et al. 2004. Stabilized nonviral formulations 
for the delivery of MCP-1 gene into cells of the vasculoendothelial 
system. Pharmaceutical Research, 21(4):683–691.
Lethbridge-Çejku M, Rose D, Vickerie J. 2006. Summary health statistics 
for U.S. Adults: National Health Interview Survey, 2004. National 
Center for Health Statistics. Vital Health Stat, 10(228).
Levitzki A. 2005. PDGF receptor kinase inhibitors for the treatment of 
restenosis. Cardiovascular Research, 65(3):581–586.
Libby P, Tanaka H. 1997. The molecular bases of restenosis. Prog Cardio-
vasc Dis, 40(2):97–106.
Liu Q, Chen ZQ, Bobustuc GC, et al. 2005. Local gene transduction of 
cyclooxygenase-1 increases blood ﬂ  ow in injured atherosclerotic rabbit 
arteries. Circulation, 111(14):1833–1840.
Lowe HC, Fahmy RG, Kavurma MM, et al. 2001. Catalytic oligodeoxy-
nucleotides deﬁ  ne a key regulatory role for early growth response 
factor-1 in the porcine model of coronary in-stent restenosis. Circ 
Res, 89(8):670–677.
Magaraggia M, Visona A, Furlan A, et al. 2006. Inactivation of vascular smooth 
muscle cells photosensitised by liposome-delivered Zn(II)-phthalocyanine. 
Journal of Photochemistry and Photobiology B: Biology, 82(1):53–58.
Maillard L, Van Belle E, Smith RC, et al. 1997. Percutaneous delivery 
of the gax gene inhibits vessel stenosis in a rabbit model of balloon 
angioplasty. Cardiovascular Research, 35(3):536–546.
Maillard L, Van Belle E, Tio FO, et al. 2000. Effect of percutaneous adeno-
virus-mediated Gax gene delivery to the arterial wall in double-injured 
atheromatous stented rabbit iliac arteries. Gene Therapy, 7(16):1353–61.International Journal of Nanomedicine 2007:2(2) 160
Brito and Amiji
Mano T, Luo Z, Malendowicz SL, et al. 1999. Reversal of GATA-6 
downregulation promotes smooth muscle differentiation and inhibits 
intimal hyperplasia in balloon-injured rat carotid artery. Circ Res, 
84(6):647–654.
Mano T, Luo Z, Suhara T, et al. 2000. Expression of wild-type and non-
cleavable fas ligand by tetracycline-regulated adenoviral vectors to 
limit intimal hyperplasia in vascular lesions. Human Gene Therapy, 
11(12):1625–1635.
Mardilovich A, Craig JA, McCammon MQ, et al. 2006. Design of a novel 
ﬁ  bronectin-mimetic peptide-amphiphile for functionalized biomaterials. 
Langmuir, 22(7):3259–3264.
Marx SO, Jayaraman T, Go LO, et al. (1995). Rapamycin-FKBP inhibits 
cell cycle regulators of proliferation in vascular smooth muscle cells. 
Circ Res, 76(3):412–417.
Meng QH, Jamal W, Hart SL, et al. 2006. Application to vascular adven-
titia of a nonviral vector for TIMP-1 gene therapy to prevent intimal 
hyperplasia. Human Gene Therapy, 17:1–11.
Mooradian DL, Hutsell TC, Keefer LK. 1995. Nitric oxide (NO) donor 
molecules: effect of NO release rate on vascular smooth muscle cell 
proliferation in vitro. J Cardiovasc Pharmacol, 25(4):674–8.
Morishita R. 2004. Perspective in progress of cardiovascular gene therapy. 
J Pharmacol Sci, 95(1):1–8.
Morishita R, Gibbons GH, Ellison KE, et al. 1994. Evidence for direct local 
effect of angiotensin in vascular hypertrophy. In vivo gene transfer of 
angiotensin converting enzyme. J Clin Invest, 94(3):978–984.
Morishita R, Gibbons GH, Horiuchi M, et al. 1995. A gene therapy strategy 
using a transcription factor decoy of the e2f binding site inhibits smooth 
muscle proliferation in vivo. PNAS, 92(13):5855–5859.
Mousavi SA, Malerod L, Berg T, et al. 2004. Clathrin-dependent endocy-
tosis. J Biochem, 377(Pt 1):1–16.
Muhs A, Heublein B, Schletter J, et al. 2003. Preclinical evaluation of 
inducible nitric oxide synthase lipoplex gene therapy for inhibition 
of stent-induced vascular neointimal lesion formation. Human Gene 
Therapy, 14(4):375–383.
Mukherjee S, Ghosh RN and Maxﬁ  eld FR. 1997. Endocytosis. Physiological 
Reviews, 77(3):759–803.
Muro S, Dziubla T, Qiu W, et al. 2006. Endothelial targeting of high-afﬁ  nity 
multivalent polymer nanocarriers directed to intercellular adhesion 
molecule 1. J Pharmacol Exp Ther, 317(3):1161–1169.
Nakatani M, Takeyama Y, Shibata M, et al. 2003. Mechanisms of restenosis 
after coronary intervention: difference between plain old balloon 
angioplasty and stenting. Cardiovasc Pathol, 12(1):40–8.
Nawarskas JJ and Osborn LA. 2005. Paclitaxel-eluting stents in coronary 
artery disease. Am J Health Syst Pharm, 62(21):2241–51.
Numaguchi Y, Okumura K, Harada M, et al. 2004. Catheter-based pros-
tacyclin synthase gene transfer prevents in-stent restenosis in rabbit 
atheromatous arteries. Cardiovascular Research, 61(1):177–185.
Ogata H, Mishio M, Luo XX, et al. 1996. Significance of elevated 
cytochrome aa3 in a state of endotoxemia in dogs. Resuscitation, 
33(1):63–68.
Ohno T, Gordon D, San H, et al. 1994. Gene therapy for vascular smooth 
muscle cell proliferation after arterial injury. Science, 265(5173):781–
784.
Pache J, Kastrati A, Mehilli J, et al. 2003. Intracoronary stenting and an-
giographic results: strut thickness effect on restenosis outcome (ISAR-
STEREO-2) trial. J Am Coll Cardiol, 41(8):1283–8.
Panyam J, Lof J, O’Leary E, et al. 2002. Efﬁ  ciency of Dispatch® and 
Inﬁ  ltrator® Cardiac Infusion Catheters in Arterial Localization of 
Nanoparticles in a Porcine Coronary Model of Restenosis. Journal of 
Drug Targeting, 10(6):515–523.
Pelisek J, Fuchs AT, Kuehnl A, et al. 2006. C-type natriuretic peptide for 
reduction of restenosis:gene transfer is superior over single peptide 
administration. The Journal of Gene Medicine, 8(7):835–844.
Pelkmans L, Helenius A. 2002. Endocytosis via caveolae. Traffic 
3(5):311–320.
Perin EC. 2005. Choosing a drug-eluting stent: a comparison between 
CYPHER and TAXUS. Rev Cardiovasc Med, 6(Suppl 1):S13–21.
Pfeiffer T, Wallich M, Sandmann W, et al. 2006. Lipoplex gene transfer of 
inducible nitric oxide synthase inhibits the reactive intimal hyperplasia 
after expanded polytetraﬂ  uoroethylene bypass grafting. Journal of 
Vascular Surgery, 43(5):1021–1027.
Puhakka HL, Turunen P, Gruchala M, et al. 2005a. Effects of vaccinia virus 
anti-inﬂ  ammatory protein 35K and TIMP-1 gene transfers on vein graft 
stenosis in rabbits. In Vivo, 19(3):515–21.
Puhakka HL, Turunen P, Rutanen J, et al. 2005b. Tissue Inhibitor of Me-
talloproteinase 1 adenoviral gene therapy alone is equally effective in 
reducing restenosis as combination gene therapy in a rabbit restenosis 
model. Journal of Vascular Research, 42(5):361–367.
Qiao T, Liu CJ, Ran F, et al. 2006. Experimental study of recombinant 
eukaryotic expression vector of human eNOS in ECV304. Swiss Med 
Wkly, 136(1–2):19–25.
Rade J, Schulick A, Virmani R, et al. 1996. Local adenoviral-mediated 
expression of recombinant hirudin reduces neointima formation after 
arterial injury. Nat Med, 2(3):293–8.
Ranade SV, Miller KM, Richard RE, et al. 2004. Physical characterization of 
controlled release of paclitaxel from the TAXUS Express2 drug-eluting 
stent. J Biomed Mater Res, A 71(4):625–34.
Ring ME. 2001. How a dentist’s name became a synonym for a life-saving 
device: the story of Dr. Charles Stent. J Hist Dent, 49(2):77–80.
Ross R. 1993. The pathogenesis of atherosclerosis: a perspective for the 
1990s. Nature, 362(6423):801–9.
Rutanen J, Markkanen J, Yla-Herttuala S. 2002. Gene therapy for restenosis: 
current status. Drugs, 62(11):1575–85.
Schatz RA, Baim DS, Leon M, et al. 1991. Clinical experience with the 
Palmaz-Schatz coronary stent. Initial results of a multicenter study. 
Circulation, 83(1):148–161.
Scheinman M AE, Kallakuri S, Hingorani A, et al. 1999. P53 gene transfer to the 
injured rat carotid artery promotes apoptosis. Surgery, 126(5):863–868.
Scheller B, Hehrlein C, Bocksch W, et al. 2006. Treatment of coronary 
in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J 
Med, 355(20):2113–2124.
Scott NA. 2006. Restenosis following implantation of bare metal coronary 
stents: Pathophysiology and pathways involved in the vascular response 
to injury. Advanced Drug Delivery Reviews, 58(3):358–376.
Serruys PW, Unger F, Sousa JE, et al. 2001. Comparison of coronary-artery 
bypass surgery and stenting for the treatment of multivessel disease. 
N Engl J Med, 344(15):1117–1124.
Shears LL, 2nd, Kibbe MR, Murdock AD, et al. 1998. Efﬁ  cient inhibition 
of intimal hyperplasia by adenovirus-mediated inducible nitric oxide 
synthase gene transfer to rats and pigs in vivo. J Am Coll Surg, 
187(3):295–306.
Shyue S-K, Tsai M-J, Liou J-Y, et al. 2001. Selective augmentation of 
prostacyclin production by combined prostacyclin synthase and 
cyclooxygenase-1 gene transfer. Circulation, 103(16):2090–2095.
Sieczkarski SB, Whittaker GR. 2002. Dissecting virus entry via endocytosis. 
The Journal Of General Virology, 83(Part 7):1535–1545.
Simari RD, San H, Rekhter M, et al. 1996. Regulation of cellular prolifera-
tion and intimal formation following balloon injury in atherosclerotic 
rabbit arteries. J Clin Invest, 98(1):225–235.
Sinnaeve P, Chiche J-D, Gillijns H, et al. 2002. Overexpression of a con-
stitutively active protein kinase g mutant reduces neointima formation 
and in-stent restenosis. Circulation, 105(24):2911–2916.
Sollott SJ, Cheng L, Pauly RR, et al. 1995. Taxol inhibits neointimal smooth 
muscle cell accumulation after angioplasty in the rat. J Clin Invest, 
95(4):1869–1876.
Sriram V, Patterson C. 2001. Cell cycle in vasculoproliferative dis-
eases: Potential interventions and routes of delivery. Circulation, 
103(19):2414–2419.
Stephan DJ, San H, Yang ZY, et al. 1997. Inhibition of vascular smooth 
muscle cell proliferation and intimal hyperplasia by gene transfer of 
beta-interferon. Molecular Medicine, 3(9):593–9.
Stephan DJ, Yang ZY, San H, et al. 1996. A new cationic liposome DNA 
complex enhances the efﬁ  ciency of arterial gene transfer in vivo. Hum 
Gene Ther, 7(15):1803–12.International Journal of Nanomedicine 2007:2(2) 161
Nanoparticulate carriers for restenosis
Stone GW, Ellis SG, Cox DA, et al. 2004. A polymer-based, paclitaxel-
eluting stent in patients with coronary artery disease. N Engl J Med, 
350(3):221–231.
Tahlil O, Brami M, Feldman LJ, et al. 1997. The dispatchTM catheter as 
a delivery tool for arterial gene transfer. Cardiovascular Research, 
33(1):181–187.
Take S, Matsutani M, Ueda H, et al. 1997. Effect of cilostazol in preventing 
restenosis after percutaneous transluminal coronary angioplasty. The 
American Journal of Cardiology, 79(8):1097–1099.
Tamai H, Igaki K, Kyo E, et al. 2000. Initial and 6-Month Results of Bio-
degradable poly-l-lactic acid coronary stents in humans. Circulation, 
102(4):399–404.
Tanner FC, Boehm M, Akyurek LM, et al. 2000. Differential effects of the cyclin-
dependent kinase inhibitors p27Kip1, p21Cip1, and p16Ink4 on Vascular 
Smooth Muscle Cell Proliferation. Circulation, 101(17):2022–2025.
Todaka T, Yokoyama C, Yanamoto H, et al. 1999. Gene transfer of human 
prostacyclin synthase prevents neointimal formation after carotid bal-
loon injury in rats editorial Comment. Stroke, 30(2):419–426.
Topol EJ. 1998. Coronary-artery stents—gauging, gorging, and gouging. 
N Engl J Med, 339(23):1702–1704.
Tsui LV, Camrud A, Mondesire J, et al. 2001. p27-p16 Fusion gene inhibits 
angioplasty-induced neointimal hyperplasia and coronary artery occlu-
sion. Circ Res, 89(4):323–328.
Tsutsui M, Shimokawa H, Higuchi S, et al. 1996. Effect of cilostazol, a 
novel anti-platelet drug, on restenosis after percutaneous transluminal 
coronary angioplasty. Jpn Circ J, 60(4):207–15.
Tulis DA, Durante W, Liu X, et al. 2001. Adenovirus-Mediated Heme 
Oxygenase-1 Gene Delivery Inhibits Injury-Induced Vascular 
Neointima Formation. Circulation, 104(22):2710–2715.
Tung R, Kaul S, Diamond GA, et al. 2006a. Narrative review: drug-eluting 
stents for the management of restenosis: A Critical appraisal of the 
evidence. Ann Intern Med, 144(12):913–919.
Tung R, Kaul S, Diamond GA, et al. 2006b. Narrative review: Drug-elut-
ing stents for the management of restenosis: a critical appraisal of the 
evidence. Annals of Internal Medicine, 144(12):913–W215.
Turunen MP, Puhakka HL, Koponen JK, et al. 2002. Peptide-retargeted 
adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases 
restenosis after intravascular gene transfer. Mol Ther, 6(3):306–12.
Turunen P, Puhakka HL, Heikura T, et al. 2006. Extracellular superoxide 
dismutase with vaccinia virus anti-inﬂ  ammatory protein 35K or tissue 
inhibitor of metalloproteinase-1: Combination gene therapy in the treat-
ment of vein graft stenosis in rabbits. Hum Gene Ther, 17(4):405–14.
Ueno H, Yamamoto H, Ito SI, et al. 1997. Adenovirus-mediated transfer of a 
dominant-negative h-ras suppresses neointimal formation in balloon-in-
jured arteries in vivo. Arterioscler Thromb Vasc Biol, 17(5):898–904.
Uwatoku T, Shimokawa H, Abe K, et al. 2003. Application of nanoparticle 
technology for the prevention of restenosis after balloon injury in rats. 
Circ Res, 92(7):62e–69.
Van Belle E, Tio FO, Chen D, et al. 1997. Passivation of metallic stents 
after arterial gene transfer of phVEGF165 inhibits thrombus formation 
and intimal thickening. Journal of the American College of Cardiology, 
29(6):1371–1379.
Varenne O, Pislaru S, Gillijns H, et al. 1998. Local adenovirus-mediated trans-
fer of human endothelial nitric oxide synthase reduces luminal narrowing 
after coronary angioplasty in pigs. Circulation, 98(9):919–926.
Virmani R, Farb A, Guagliumi G, et al. 2004. Drug-eluting stents: caution 
and concerns for long-term outcome. Coron Artery Dis, 15(6):313–8.
Vishnevetsky D, Patel P, Tijerino H, et al. 2004. Sirolimus-eluting coronary 
stent. Am J Health Syst Pharm, 61(5):449–56.
Voisard R, Dartsch PC, Seitzer U, et al. 1993. The in-vitro effect of anti-
neoplastic agents on proliferative activity and cytoskeletal components 
of plaque-derived smooth-muscle cells from human coronary arteries. 
Coron Artery Dis, 4(10):935–42.
Voisard R, Seitzer U, Baur R, et al. 1995. A prescreening system for potential 
antiproliferative agents: implications for local treatment strategies of postan-
gioplasty restenosis. International Journal of Cardiology, 51(1):15–28.
von der Leyen HE, Gibbons GH, Morishita R, et al. 1995. Gene therapy 
inhibiting neointimal vascular lesion: in vivo transfer of endothelial 
cell nitric oxide synthase gene. PNAS, 92(4):1137–1141.
Waksman R. 2006. Biodegradable stents: they do their job and disappear. 
J Invasive Cardiol, 18(2):70–4.
Wang K, Kessler PD, Zhou Z, et al. 2003. Local adenoviral-mediated 
inducible nitric oxide synthase gene transfer inhibits neointimal for-
mation in the porcine coronary stented model. Molecular Therapy, 
7(5):597–603.
Weissleder R, Kelly K, Sun EY, et al. 2005. Cell-speciﬁ  c targeting of 
nanoparticles by multivalent attachment of small molecules. Nat Bio-
tech, 23(11):1418–1423.
Welt FGP, Edelman ER, Simon DI, et al. 2000. Neutrophil, not macrophage, 
inﬁ  ltration precedes neointimal thickening in balloon-injured arteries. 
Arterioscler Thromb Vasc Biol, 20(12):2553–2558.
Welt FGP and Rogers C. 2002. Inﬂ  ammation and restenosis in the stent era. 
Arterioscler Thromb Vasc Biol, 22(11):1769–1776.
Westedt U, Barbu-Tudoran L, Schaper AK, et al. 2002. Deposition of 
nanoparticles in the arterial vessel by porous balloon catheters: 
Localization by confocal laser scanning microscopy and transmission 
electron microscopy. AAPS PharmSci, 4(4):Article 41 pages 1–6.
Westedt U, Barbu-Tudoran L, Schaper AK, et al. 2004. Effects of different 
application parameters on penetration characteristics and arterial vessel 
wall integrity after local nanoparticle delivery using a porous balloon 
catheter. Eur J Pharm Biopharm, 58(1):161–8.
Wieneke H, Dirsch O, Sawitowski T, et al. 2003. Synergistic effects of 
a novel nanoporous stent coating and tacrolimus on intima prolif-
eration in rabbits. Catheterization and Cardiovascular Interventions, 
60(3):399–407.
Wills KN, Mano T, Avanzini JB, et al. 2001. Tissue-speciﬁ  c expression of 
an anti-proliferative hybrid transgene from the human smooth muscle 
alpha-actin promoter suppresses smooth muscle cell proliferation and 
neointima formation. Gene Therapy, 8(24):1847–54.
Wu GY, Wu CH. 1988. Receptor-mediated gene delivery and expression 
in vivo. J Biol Chem, 263(29):14621–14624.
Wu KK. 1997. Prostacyclin and nitric oxide-related gene transfer in 
preventing arterial thrombosis and restenosis. Agents Actions Suppl, 
48:107–23.
Yin X, Yutani C, Ikeda Y, et al. 2002. Tissue factor pathway inhibitor gene 
delivery using HVJ-AVE liposomes markedly reduces restenosis in 
atherosclerotic arteries. Cardiovascular Research, 56(3):454–463.
Yonemitsu Y, Kaneda Y, Tanaka S, et al. 1998. Transfer of wild-type p53 
gene effectively inhibits vascular smooth muscle cell proliferation in 
vitro and in vivo. Circ Res, 82(2):147–156.
Zoldhelyi P, Chen ZQ, Shelat HS, et al. 2001. Local gene transfer of tissue 
factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic 
arteries. PNAS, 98(7):4078–4083.